Xcout Intel
Infinity Bio, Inc.
Infinity Bio, Inc. is a biotechnology research company that provides detailed insights into the immune system utilizing its proprietary antibody reactome profiling platform.
Subscribe to see Infinity Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Infinity Bio, Inc. at a glance
Infinity Bio, Inc. is a healthcare technology systems company headquartered in United States. Its most recent funding round, Series A, raised $8M in June 2025. Xcout tracks 17 named people at Infinity Bio, Inc., including Joy M Nassif (Chief Executive Officer).
Infinity Bio, Inc. leadership
- Joy M NassifChief Executive Officer
- Joy NassifChief Executive Officer
- Ben Larmanco-founder
- Benjamin LarmanExecutive Officer
- H. Benjamin LarmanExecutive Officer
- Joy M NassifExecutive Officer
11 more named people on record for Infinity Bio, Inc., with roles, board committees and tenure — see the full roster →
Infinity Bio, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $8M | 1 named | |
| SEC Form D filing | $2M | — | |
| SEC Form D filing | $4.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Infinity Bio, Inc. competitors
A few of Infinity Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Adaptive Biotechnologies Corp. is a biotechnology company headquartered in Seattle, Washington, United States. The firm focuses on decoding and analyzing the human immune system to address various diseases.
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
FBB Biomed, Inc. provides an RNA analytics platform that uses blood RNA-seq data to quantify real-time gene activity and generate biological signatures for chronic diseases. The company serves diagnostic laboratories seeking to offer novel monitoring tests and biopharmaceutical companies needing tools to stratify clinical trial participants and measure individual responses.
SomaLogic, Inc. is an active biotechnology company headquartered in Boulder, Colorado, specializing in proteomics technology and biomarker discovery.
IMU Biosciences is headquartered in London, United Kingdom, and operates in the biotechnology sector. The company develops data platforms and immunological profiling technologies supported by a growing scientific team.
Get Infinity Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Infinity Bio, Inc. in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access